Neutralising antibodies to interferon β in multiple sclerosis
- 188 Downloads
Interferon beta (IFNβ) therapy for multiple sclerosis (MS) is associated with a potential for the development of neutralising antibodies (NAbs) that negatively affect therapy. Several factors influence the development of NAbs, such as lack of complete sequence homology with the endogenous IFNβ sequence, frequency of administration, level of dose and formulation of IFNβ. Taken together, the evidence that NAb status reduces clinical efficacy in MS patients is strong. Standardised assays for NAbs are lacking, and titres vary over time. NAb testing is a critical component of care for MS patients because it provides information on one of the most important factors determining clinical responsiveness to IFNβ therapy. This expert panel report attempts to move the field towards resolution of the remaining issues and considers several aspects of NAbs, including their clinical relevance, factors influencing immunogenicity, assays to quantify NAbs and the definition of clinically relevant titres.
Key wordsneutralising antibodies interferon β multiple sclerosis NAb+ NAb-
Unable to display preview. Download preview PDF.
- 7.IFNβ Multiple Sclerosis Study Group, the University of British Columbia MS/MRI Analysis Group (1996) Neutralizing antibodies during treatment of multiple sclerosis with interferon beta- 1b: experience during the first three years. Neurology 47:889–894Google Scholar
- 11.Herndon RM, Jacobs LD, Coats ME, et al. (1999) Results of an ongoing, open-label, safety-extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis. Int J MS Care 1:1–6Google Scholar
- 16.PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group, the University of British Columbia MS/MRI Analysis Group (2001) PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 56:1628–1636Google Scholar
- 23.Deisenhammer F, Reindl M, Harvey J, et al. (1999) Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 52:1239–1243Google Scholar
- 29.Patten PA, Schellekens H (2003) The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development. Dev Biol 112:81–87Google Scholar
- 38.WHO Expert Committee on Biological Standardization (1985) Thirty-fifth report. World Health Organization Technical Report Series 725. World Health Organization, Geneva, SwitzerlandGoogle Scholar
- 51.Giovannoni, G, Barbarash OL, Jaber A, et al. on behalf of the RNF Study Group (2006) Reduced immunogenicity with a new formulation of interferon-beta-1a (Rebif): 24-week results of a phase IIIb study. Mult Scler 12 (suppl 1):P675Google Scholar